Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes

P and T

Volumn 35, Issue 9, 2010, Pages 509-513

  Pathak, Rolee ^a,b   Bridgeman, Mary Barna ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^c Capital Health Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS SAXAGLIPTIN; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; KETOCONAZOLE; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN; PIOGLITAZONE; PIOGLITAZONE PLUS SITAGLIPTIN; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SAXAGLIPTIN PLUS THIAZOLIDINEDIONE; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; EDEMA; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RHINOPHARYNGITIS; STEVENS JOHNSON SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 77957149259     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Centers for Disease Control and Prevention (CDC). National Diabetes Fact Sheet: General information and national estimates on diabetes in the United States, 2007. Atlanta: U.S. Department of Health and Human Services, CDC; 2008.
2. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 2009;49: S16-S29.
3. Verspohl EJ. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like-peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009;124:113-138.
4. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
5. Moore B, Edie ES, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1906;1:28-38.
6. Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007;28:315-322.
7. Onglyza (saxagliptin), package insert. Princeton, N.J.: Bristol-Myers Squibb; July 2009.
8. Herman GA, Bergman AB, Hillard D, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-688.
9. Januvia (sitagliptin), package insert. Whitehouse Station, N.J.: Merck & Co., Inc.; February 2010.
10. Bergman AJ, Cote JC, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-1864.
11. Migoya EM, Stevens CH, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009;16(1):e165-e170.
12. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-688.
13. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619.
14. Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily oral doses of saxagliptin for two weeks in type 2 diabetic and healthy subjects (Abstract 606-P). Paper presented at the 37th annual meeting of the American Diabetes Association, Chicago, June 22-26, 2007.
15. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-2571.
16. Charbonnel B, Karasik A, Liu JM, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-2643. (Pubitemid 44912191)
17. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-1568. (Pubitemid 44841980)
18. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655.
19. Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94:4810-4819.
20. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with up-titration of sulphonylurea in patients with type 2 diabetes: A randomized controlled trial. Int J Clin Pract 2009;63:1395-1406.
21. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33:S11-S61.
22. FDA. Information for healthcare professionals. Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). September 25, 2009. Available at: www.fda.gov/ Drugs/ Drug Safety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm. Accessed May 14, 2010.
23. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203.
24. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-484.
25. Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: Final data for 2007. National vital statistics reports, web release. Vol 58, No. 19. Hyattsville, Md: National Center for Health Statistics; May 2010.